Downstream of Ras, the
serine/threonine kinase B-raf has been reported to be mutated, amongst other
carcinomas, in a substantial subset of primary
melanomas, with a preponderance of mutations within the
kinase domain, including the activating V599E and V599K transitions. We investigated a representative series of 54 resection specimens of
melanoma lymph node metastases for the presence of mutations within the activation segment (exon 15) of the
B-raf kinase domain by polymerase chain reaction (PCR) and single-strand conformational polymorphism (SSCP) gel electrophoresis. Sequencing of cloned PCR-SSCP amplicons resulted in 24 (44%) samples harbouring somatic mutations, which is not significantly different from the mutation frequency found in recently investigated primary cutaneous
melanomas (Deichmann M, Thome M, Benner A, Näher H. B-raf exon 15 mutations are common in primary
melanoma resection specimens but not associated with clinical outcome. Oncology 2004; 66:411-419). The activating mutation T1796A was present in 20 (83%) of these resection specimens, followed in frequency by the oncogenic g1795A mutation in five (21%) cases. With regard to the B-raf
protein sequence, the
acidic amino acid transitions V599E and V599K were predicted in 15 (62%) and five (21%) of the 24 positive
metastases, respectively. The detection of mutations at this hot spot
codon was significantly associated with subsequent visceral
metastasis (P=0.03; Fisher's exact test). During the transition from primary
melanomas (see reference above) to
lymph node metastases, the spectrum of B-raf mutations narrows significantly (P=0.00047). The oncogenic B-raf mutations V599E and V599K, as early events in melanocyte transformation, persist throughout
metastasis with important prognostic implications.